Bydureon

( DrugBank: - / KEGG DRUG: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	4

告示番号	疾患名（ページ内リンク）	臨床試験数
17	多系統萎縮症	2

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

trials per page:

Showing 1 to 4 of 4 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04232969 (ClinicalTrials.gov)	January 20, 2020	10/1/2020	Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Diseas ...	A Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Week ...	Parkinson's Disease	Drug: Exenatide extended release 2mg (Bydureon)	University College, London	NULL	Active, not recruiting	25 Years	80 Years	All	194	Phase 3	United Kingdom
2	EUCTR2019-000732-26-SE (EUCTR)	23/10/2019	07/05/2019	Exenatide Treatment in Parkinson's Disease	Effect of Exenatide on disease progression in early Parkinson's disease.	Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Bydureon2 mg powder and solvent for prolonged-release suspension Product Name: BYDUREON IN ...	Stockholm Health Care Services	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	Sweden
3	EUCTR2018-003028-35-GB (EUCTR)	04/09/2019	15/11/2019	A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once week ...	A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once week ...	Parkinson's disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parki ...	Trade Name: Bydureon Product Name: Bydureon INN or Proposed INN: Exenatide	University College London Comprehensive Clinical Trial Unit	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 3	United Kingdom
4	EUCTR2013-003363-64-GB (EUCTR)	03/04/2014	11/03/2014	Trial of Exenatide for Parkinson's disease	A randomised, double blind, placebo controlled, single centre, 60 week trial of Exenatide once weekl ...	Parkinson's Disease MedDRA version: 16.1;Level: LLT;Classification code 10013113;Term: Disease Parki ...	Trade Name: Bydureon Product Name: Exenatide INN or Proposed INN: exenatide	University College London	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United Kingdom

First Previous1Next Last

17. 多系統萎縮症

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04431713 (ClinicalTrials.gov)	September 16, 2020	29/5/2020	Exenatide Once-weekly as a Treatment for Multiple System Atrophy	An Open Label, Single Site, 48 Week, Randomised Controlled Trial Evaluating the Safety and Efficacy ...	Multiple System Atrophy	Drug: Exenatide Pen Injector [Bydureon]	University College, London	NULL	Recruiting	30 Years	80 Years	All	50	Phase 2	United Kingdom
2	EUCTR2020-000122-26-GB (EUCTR)	11/05/2020	06/04/2020	Exenatide once-weekly as a treatment for Multiple System Atrophy.	A Phase IIa, open label, single-site, 48 week randomised controlled trial evaluating the safety and ...	Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple s ...	Trade Name: Bydureon Product Name: Bydureon INN or Proposed INN: Exenatide	University College London (UCL)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 2	United Kingdom

First Previous1Next Last